TrialsgrambêtaRCTs are beautiful
ESC Congress 2026Présenté dim. 30 août · 11:15 UTC+2Hot Line 7Tous les essais Hot Line →

TAVI PCI

2026

Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention — The TAVI PCI Trial

In 986 patients with severe aortic stenosis and coronary disease, PCI after TAVI was non-inferior to PCI before TAVI for death, myocardial infarction, revascularisation, rehospitalisation or major bleeding at 1 year.

Résultat

composite of all-cause death, non-fatal myocardial infarction, ischaemia-driven revascularisation, valve- or procedure-related rehospitalisation (including heart failure), or life-threatening/disabling or major bleeding at 1 year
Différence absolue
2,0 points
Estimation de l’effet

risk difference-2,0IC à 95 % -7,4 to 3,4 · P < 0,001

La différence absolue est dérivée des taux d’événements.

Également rapporté: BARC 3a or worse bleeding 6.6% vs 9.7%.

Publication originale
Sous-thème
TAVR and PCI
Schéma
prospective, international, multicentre (Austria, France, Germany, Italy, Netherlands, Switzerland), open-label, 2-arm RCT; 1:1 PCI after TAVI vs PCI before TAVI (each within 1–45 days); non-inferiority; primary endpoint at 1 year, follow-up to 5 years
Pertinence
Important: l’un des piliers parmi d’autres.
Source
Stähli BE, et al. N Engl J Med. 2026; published online 30 August.doi 10.1056/nejmoa2606924

Discussion et critique

Sequence, not indication: everyone got both procedures, and the question was only which comes first. Doing the valve first is not worse, and it bleeds less: 6.6% vs 9.7%, which is the practical argument, since PCI first means antiplatelet therapy running through the valve procedure. Non-inferiority with a margin wide enough to admit a 3.4-point excess, in a mean age of 82, so this licenses a preference rather than settling a mechanism.